Our Story
The CB2 Story
“If medical cannabis wants to play in the same sandbox as traditional pharmaceuticals, then it needs to start acting like a traditional medicine.”
Prad Sekar, CEO of CB2 Insights

Traditional Healthcare Protocol for Cannabis

In 2014, healthcare entrepreneurs Prad Sekar and Kash Qureshi were asked to help educate physicians across Canada on how best to prescribe medical cannabis to a rapidly growing patient population. At a time where social stigma, limited medical research and the overall complexity of prescribing cannabis as a medicine all converged, Sekar and Qureshi knew that they would have to bring traditional healthcare protocols to the cannabis industry before the cannabis industry could properly integrate with healthcare.

Cannabis-Specific EMR System

In the effort to bring traditional healthcare protocols to the cannabis industry, a need to integrate medical cannabis evaluations and standardized clinical data capturing was realized, and Sail was created. Sail became the first ever Electronic Medical Record system built with cannabis-specific workflows.

This industry-leading EMR system allowed physicians to use one platform to manage their clinic, use standardized methods of collecting patient data and evaluate patients for medical cannabis. In order to increase adoption of these traditional protocols by clinics, a successful multi-state clinic group in the US was bought by the company. Thus, bringing the technology and protocols into the day-to-day operations of these clinics.

The Largest Cannabis Patient Registry

Today, CB2 Insights is recognized as having the largest cannabis patient registry in the US, owning and operating the largest collection of medical cannabis evaluation centers in the US. The company’s clinical operations span 13 states, managing nearly 100,000 patients annually.

Unparalleled Cannabis Data

With millions of clinically-validated data points collected through our own clinic network, we can produce research and insights to drive Real-World Evidence specific to the safety and efficacy of medical cannabis treatment.

The Industry’s First CDS Tool

With the success of the company’s proprietary practice management and data collection tool, CB2 Insights developed the industry’s first Clinical Decision Support tool to help guide physicians when prescribing medical cannabis. The tool is powered by data and clinical research.

The company gained traction in international markets which eventually led to the acquisition of a large cannabis evaluation center group in the US which has since grown to become the largest multi-state cannabis evaluation and education group in the country.

Full Service CRO

Using extensive experience and the existing infrastructure within CB2 Insights' technology and processes, we offer end-to-end clinical Contract Research Organization services to help with research, development and commercialization of products. Our suite of data and technology solutions and existing patient registries can be utilized for a range of services such as prospective and retrospective research, conduct clinical trials, analyses, and generate publications.

International Reach

As CB2 Insights grows, we are expanding internationally, operating in Canada, United States, United Kingdom and Colombia. In addition to our global offices, we continue to work with partners worldwide as we advance medical cannabis research efforts.

And we’ve only just begun!